BioGaia ABBGLAF 100 Cash Ratio is 3.27 as of Mar. 2026, which is 13% below its 10-year median of 3.74. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $12.54 (Fairly Valued). The stock has 5 warning signs investors should review. Among 975 Drug Manufacturers companies, BioGaia AB ranks better than 86.87% on this metric.
BioGaia AB has a Cash Ratio of 3.27. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for BioGaia AB's Cash Ratio or its related term are showing as below:
BGLAF'
s Cash Ratio Range Over the Past 10 Years
Min: 1.08 Med: 3.74 Max: 14.7
Current: 3.27
During the past 13 years, BioGaia AB's highest Cash Ratio was 14.70. The lowest was 1.08. And the median was 3.74.
BGLAF's Cash Ratio is ranked better than 86.87% of 975
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs BGLAF: 3.27
BioGaia AB (OTCPK:BGLAF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
BioGaia AB Cash Ratio Related Terms
BioGaia AB Cash Ratio Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB (BGLAF) has a Cash Ratio of 3.27 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on BioGaia AB and its competitors. This is 13% below median its historical median of 3.74. Over the past decade, BioGaia AB's Cash Ratio has ranged from 1.08 to 14.70. According to the industry distribution chart, BioGaia AB ranks #128 out of 975 companies in the Drug Manufacturers industry, placing it in the top 13.1%.
Is BioGaia AB's Cash Ratio too high?
BioGaia AB's current Cash Ratio of 3.27 is 13% below median its 10-year median of 3.74. Over the past 10 years, this metric has ranged from a low of 1.08 to a high of 14.70. The Drug Manufacturers industry median Cash Ratio is 0.61. BioGaia AB's value of 3.27 is 436.1% above this industry median. Based on the distribution chart, BioGaia AB ranks #128 out of 975 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Cash Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #128 out of 975 companies for Cash Ratio. This places BioGaia AB in the top 13% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.61. BioGaia AB's value of 3.27 is 436.1% above this benchmark. Historically, BioGaia AB's own Cash Ratio has ranged from 1.08 to 14.70 over the past decade. While the company's 10-year median is 3.74 vs. the industry median of 0.61, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.61, based on 975 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Cash Ratio of 3.27 is 436.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Cash Ratio is 3.27, which is 13% below median its own 10-year median of 3.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Fairly Valued. The stock's GF Value™ is $12.54, compared to a current price of $12.20 — trading 2.7% below its estimated fair value. The current Cash Ratio is 3.27, which is 13% below median its 10-year median of 3.74 and 436.1% above the Drug Manufacturers industry median of 0.61. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Cash Ratio is 3.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 2.7% below its estimated GF Value™ of $12.54.
GuruFocus considers BioGaia AB to be Fairly Valued.
Key valuation signals for BGLAF:
Cash Ratio: 3.27 (13% below median its 10-year median of 3.74)
GF Value™: $12.54 vs. price of $12.20 (2.7% below fair value)
Industry Position: 436.1% above the Drug Manufacturers median (#128 of 975)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
